2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines recommend a binary distinction between HER2-positive and HER2-negative breast cancers to guide clinicians’ treatment decision. This evidence concerns the gene ERBB2 and breast carcinoma.